OncoMatch/Clinical Trials/NCT06740240
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
Is NCT06740240 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-FAPI-Biotin and 68Ga-FAPI/18F-FDG for tumor.
Treatment: 68Ga-FAPI-Biotin · 68Ga-FAPI/18F-FDG — As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Check if I qualifyEligibility summary
For patients with Tumor.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Frequently asked questions
Is NCT06740240 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify